Close Menu

cancer of unknown primary

The field is collecting evidence supporting genomics-guided care but experts are still awaiting prospective data and grappling with other challenges.

The project is collaborating with nine biopharma companies to combine more real-world clinical data with genomic data.

The study of cancer immunity biomarkers revealed complex immune profiles for most tumors, suggesting the need for customized combinations of immunotherapies.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

The new center will bring together pathology, computer science, cancer genomics, and immunogenomics to study which cancer patients can benefit from immunotherapy.

Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.

A new study suggests that using rotavirus in combination with immune checkpoint blockade therapy could give oncologists a new way to treat pediatric cancers.

Negative results in recent trials have highlighted the challenges that newer genomic test makers must overcome in proving methods for personalized CUP treatment.

A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.

The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.

Pages